Dr. Mitin is a Russian-born, U.S.-trained academic radiation oncologist with the commitment to improve patient care in both countries through clinical research and education.  He is an Associate Professor at Oregon Health and Science University and a medical director of the Tuality/OHSU Cancer Center. Dr. Mitin is a native of Moscow, Russia, who came to the United States at age 16 to pursue his education. He graduated cum Laude from Cornell University, completed a combined MD/PhD program at Tufts University School of Medicine and received clinical training in radiation oncology at Harvard Radiation Oncology Program in Boston.  He was invited to join the faculty of Harvard Medical School at the Massachusetts General Hospital, where he worked for 2 years before relocating to Oregon.

Dr. Mitin has been involved in educational programs organized by RUSSCO, including giving lectures and contouring workshops to Russian physicians ( during the annual conferences held in Moscow, Russia. Through these educational collaborations, he has co-authored several manuscripts with Russian colleagues (The Red Beam: Past, Present and Future of Radiation Oncology in Russia. Likhacheva A, Mitin T and Khmelevskiy E. IJROBP, 2017; Current Role of Radiotherapy for Renal Cell Carcinoma: Review. Dengina N, Tsimafeyeu I and Mitin T. Clinical Genitourinary Cancer 2016). He has carried out several large scale clinical analyses through national cooperative groups, such as Radiation Therapy Oncology Group (RTOG), analyzed data and published the results in high-impact journals (Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu C-L, Buyyounouski MK, Sandler H, Zietman AL. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomized multicentre phase 2 trial. Lancet Oncology. 2013 Aug;14(9):863-72).